Jonirai Schmidt
Physician Assistant · Lancaster, TXNPI 1427039643
Payments from drug & device makers
Across 124 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$655
- GSK$377
- Lilly USA, LLC$279
- AstraZeneca$167
- Boehringer Ingelheim$139
- Dexcom, Inc.$79
- plus $467 from 17 others
What the payments were for
- Food & beverage$2,164100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $655 |
| GSK | 21 | $377 |
| Lilly USA, LLC | 18 | $279 |
| AstraZeneca | 11 | $167 |
| Boehringer Ingelheim | 6 | $139 |
| Dexcom, Inc. | 5 | $79 |
| Bayer | 3 | $53 |
| Exact Sciences | 2 | $45 |
| Abbott | 2 | $42 |
| Astellas Pharma US Inc | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Orexo US, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $15 |
| Phadia US Inc. | 1 | $12 |
How this compares
$2,164 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $133,604 |
| JardianceEmpagliflozin | 62 | $54,600 |
| TrulicityDulaglutide | 14 | $26,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $26,256 |
| EliquisApixaban | 15 | $21,400 |
| JanuviaSitagliptin Phosphate | 17 | $18,676 |
| MounjaroTirzepatide | 11 | $17,695 |
| TradjentaLinagliptin | 12 | $14,748 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $13,197 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $4,306 |
| Nifedipine ErNifedipine | 48 | $2,352 |
| Gabapentin | 130 | $2,127 |
| Atorvastatin Calcium | 234 | $1,806 |
| Fluticasone Propionate | 129 | $1,670 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $655 | $133,60483 claims |
| Boehringer IngelheimJardiance, Tradjenta | $139 | $69,34874 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $279 | $43,95425 claims |
| GSKTrelegy Ellipta | $377 | $26,25623 claims |
| AstraZenecaBreztri Aerosphere | $167 | $13,19716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Lancaster
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.